Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07225764 · ClinicalTrials.gov registry record · Phase 4

CaOx Stone Prevention

A Phase 4 study of Kidney Stones, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
Phase 4
Development phase
80
Enrollment target
1
Study location

NCT07225764 is a Phase 4 study of Kidney Stones that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 80 participants, below the 290-participant average among 15 other Kidney Stones trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07225764, a Phase 4 study of Kidney Stones, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
Phase 4
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

This single-center randomized controlled trial at Mount Sinai West will enroll 80 patients undergoing percutaneous nephrolithotomy for calcium oxalate stones. Participants will be randomized to receive either empiric therapy or selective therapy guided by 24-hour urine evaluation. The primary outcome is change in calcium oxalate supersaturation at 4 weeks, aiming to determine whether empiric therapy can provide outcomes comparable to selective therapy while simplifying access to prevention.

Conditions Studied

Interventions

  • DRUG Chlorthalidone
  • BEHAVIORAL Low oxalate diet

Study Locations (1)

New York

  • Mount Sinai West - New York

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-10-23
Est. Completion 2027-06-30
Phase Phase 4

What the Registry Record Tells You About NCT07225764

The ClinicalTrials.gov registry entry for NCT07225764 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 290-participant average among 15 other Kidney Stones trials with a reported enrollment target (72% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Kidney Stones appearing as the primary indexed condition, and to 2 interventions - of which Chlorthalidone is the first listed.

NCT07225764 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT07225764 about?

NCT07225764 is a clinical study titled "CaOx Stone Prevention". This single-center randomized controlled trial at Mount Sinai West will enroll 80 patients undergoing percutaneous nephrolithotomy for calcium oxalate stones. Participants will be randomized to receive either empiric therapy or selective therapy guided by 24-hour urine evaluation. The primary outcom...

What is the current status of trial NCT07225764?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2025-10-23. Estimated completion is 2027-06-30.

What conditions does trial NCT07225764 study?

This clinical trial studies the following conditions: Kidney Stones.

What interventions are being tested in trial NCT07225764?

The interventions under investigation include: Chlorthalidone (DRUG), Low oxalate diet (BEHAVIORAL).

Who is sponsoring clinical trial NCT07225764?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07225764 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Kidney Stones

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.